The DOI matches its Crossref record.
Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at Eight Years by 'Nolvadex'/Adjuvant Trial Organisation.
Open accessAbstract
At a maximum follow up of 8 years (median 5 years 6 months) in a randomised trial of adjuvant tamoxifen versus no treatment as therapy for early breast cancer, a significant advantage persists for patients receiving 20 mg of tamoxifen daily for 2 years. This advantage is independent of menopausal status, stage, grade and ER status. Log hazard rate analysis fails to demonstrate a rebound effect on stopping the drug and suggests that more prolonged treatment might further improve results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
Early Breast Cancer Trialist's Collaborative Group (1992) · The Lancet · doi:10.1016/0140-6736(92)90997-h · Cited by 2,182
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
Fornander, T., Cedermark, B., Mattsson, A., Skoog, L., Theve, T., Askergren, J., Rutqvist, L., Glas, U., Silfverswärd, C., Somell, A., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91141-0 · Cited by 920
Tamoxifen: a most unlikely pioneering medicine
Jordan, V. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1031 · Cited by 824
Metadata
- Authors
- 'Nolvadex', A. A. E. Y. B., & Adjuvant Trial Organisation.
- Venue
- British Journal of Cancer
- Published
- 1988-12
- Volume
- 57
- Issue
- 6
- Pages
- 608-611
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W4246467214
- Cited by
- 250
- References
- 0
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at Eight Years by 'Nolvadex'/Adjuvant Trial Organisation. https://app.cochat.ai/papers/10.1038/bjc.1988.138
- The paper
- 'Nolvadex', A. A. E. Y. B., & Adjuvant Trial Organisation. (1988). Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer: Analysis at Eight Years by 'Nolvadex'/Adjuvant Trial Organisation. British Journal of Cancer. https://doi.org/10.1038/bjc.1988.138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.